Literature DB >> 22085227

Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.

A Palmieri1, C Imbimbo, M Creta, P Verze, F Fusco, V Mirone.   

Abstract

Extracorporeal shock wave therapy improves erectile function in patients with Peyronie's disease. However, erectile dysfunction still persists in many cases. We aimed to investigate the effects of extracorporeal shock wave therapy plus tadalafil 5 mg once daily in the management of patients with Peyronie's disease and erectile dysfunction not previously treated. One hundred patients were enrolled in a prospective, randomized, controlled study. Patients were randomly allocated to receive either extracorporeal shock wave therapy alone for 4 weeks (n = 50) or extracorporeal shock wave therapy plus tadalafil 5 mg once daily for 4 weeks (n = 50). Main outcome measures were: erectile function (evaluated through the shortened version of the International Index of Erectile Function), pain during erection (evaluated through a Visual Analog Scale), plaque size, penile curvature and quality of life (evaluated through an internal questionnaire). Follow-up evaluations were performed after 12 and 24 weeks. In both groups, at 12 weeks follow-up, mean Visual Analog Scale score, mean International Index of Erectile Function score and mean quality of life score ameliorated significantly while mean plaque size and mean curvature degree were unchanged. Intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and quality of life score in patients receiving the combination. After 24 weeks, intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and mean quality of life score in patients that received extracorporeal shock wave therapy plus tadalafil. In conclusion extracorporeal shock wave therapy plus tadalafil 5 mg once daily may represent a valid conservative strategy for the management of patients with Peyronie's disease and erectile dysfunction.
© 2011 The Authors. International Journal of Andrology © 2011 European Academy of Andrology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22085227     DOI: 10.1111/j.1365-2605.2011.01226.x

Source DB:  PubMed          Journal:  Int J Androl        ISSN: 0105-6263


  27 in total

1.  PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2015-06-01

Review 2.  Contemporary Review of Peyronie's Disease Treatment.

Authors:  Edward Capoccia; Laurence A Levine
Journal:  Curr Urol Rep       Date:  2018-05-17       Impact factor: 3.092

3.  2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature.

Authors:  Anthony J Bella; Jay C Lee; Ethan D Grober; Serge Carrier; Francois Benard; Gerald B Brock
Journal:  Can Urol Assoc J       Date:  2018-02-22       Impact factor: 1.862

4.  Peyronie's Disease: AUA Guideline.

Authors:  Ajay Nehra; Ralph Alterowitz; Daniel J Culkin; Martha M Faraday; Lawrence S Hakim; Joel J Heidelbaugh; Mohit Khera; Erin Kirkby; Kevin T McVary; Martin M Miner; Christian J Nelson; Hossein Sadeghi-Nejad; Allen D Seftel; Alan W Shindel; Arthur L Burnett
Journal:  J Urol       Date:  2015-06-09       Impact factor: 7.450

Review 5.  Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.

Authors:  Ayad Yousif; Caleb Natale; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2021-01-08       Impact factor: 3.092

Review 6.  Low-intensity shockwave therapy for erectile dysfunction: is the evidence strong enough?

Authors:  Mikkel Fode; Georgios Hatzichristodoulou; Ege Can Serefoglu; Paolo Verze; Maarten Albersen
Journal:  Nat Rev Urol       Date:  2017-07-25       Impact factor: 14.432

Review 7.  A meta-analysis of extracorporeal shock wave therapy for Peyronie's disease.

Authors:  L Gao; S Qian; Z Tang; J Li; J Yuan
Journal:  Int J Impot Res       Date:  2016-06-02       Impact factor: 2.896

Review 8.  Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.

Authors:  Fuxun Zhang; Feng Qin; Jiuhong Yuan
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

9.  Management of Patients With Normal Physical Exams and Ultrasound Evidence of Isolated Septal and Punctate Penile Scarring.

Authors:  Noah Stern; Nahid Punjani; Gerald Brock
Journal:  Sex Med       Date:  2021-05-30       Impact factor: 2.491

10.  Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease.

Authors:  Lucio Dell'Atti
Journal:  Urol Ann       Date:  2015 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.